1. Home
  2. CRNT vs TLSI Comparison

CRNT vs TLSI Comparison

Compare CRNT & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ceragon Networks Ltd.

CRNT

Ceragon Networks Ltd.

SELL

Current Price

$2.05

Market Cap

213.6M

Sector

Technology

ML Signal

SELL

Logo TriSalus Life Sciences Inc.

TLSI

TriSalus Life Sciences Inc.

HOLD

Current Price

$4.01

Market Cap

250.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRNT
TLSI
Founded
1996
2010
Country
Israel
United States
Employees
N/A
N/A
Industry
Radio And Television Broadcasting And Communications Equipment
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
213.6M
250.0M
IPO Year
2000
2020

Fundamental Metrics

Financial Performance
Metric
CRNT
TLSI
Price
$2.05
$4.01
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
5
Target Price
$4.83
★ $10.40
AVG Volume (30 Days)
310.1K
★ 316.9K
Earning Date
11-10-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $45,151,000.00
Revenue This Year
$9.08
$17.65
Revenue Next Year
$6.40
$40.27
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 53.41
52 Week Low
$1.85
$2.20
52 Week High
$3.29
$7.95

Technical Indicators

Market Signals
Indicator
CRNT
TLSI
Relative Strength Index (RSI) 46.02 34.71
Support Level $2.03 $3.64
Resistance Level $2.17 $4.48
Average True Range (ATR) 0.07 0.30
MACD -0.00 -0.03
Stochastic Oscillator 28.95 6.57

Price Performance

Historical Comparison
CRNT
TLSI

About CRNT Ceragon Networks Ltd.

Ceragon Networks Ltd is a wireless transport specialist, providing wireless connectivity solutions to markets globally across various industries, including wireless (mobile) network service providers and private networks, enabling them to build new networks and evolve networks towards 4G and 5G services. Its portfolio mainly comprises the IP-20 and IP-50 product series, including integrated multi-technology radio units operating across frequencies from 4 GHz to 86 GHz, as well as single-radio devices used for wireless data transport. Additionally, the company offers turnkey services including: network and radio planning, site survey, installation, network auditing and optimization, and more. Geographically, it derives maximum revenue from India, followed by North America and other regions.

About TLSI TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.

Share on Social Networks: